Chi-Kin Chow

419 total citations
10 papers, 325 citations indexed

About

Chi-Kin Chow is a scholar working on Hepatology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Chi-Kin Chow has authored 10 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Hepatology, 3 papers in Molecular Biology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Chi-Kin Chow's work include Liver physiology and pathology (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Chi-Kin Chow is often cited by papers focused on Liver physiology and pathology (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Chi-Kin Chow collaborates with scholars based in United States. Chi-Kin Chow's co-authors include Jirong Lu, Barrett W. Allan, Victor J. Wroblewski, Holly A. Bina, James Nelson, Ying Tang, Jonathan W. Tetreault, Ling Liu, Kristine Kikly and Lihua Huang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Drug Metabolism and Disposition.

In The Last Decade

Chi-Kin Chow

10 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chi-Kin Chow United States	5	174	134	130	66	61	10	325
Mary Birchler United States	8	131 0.8×	140 1.0×	111 0.9×	27 0.4×	6 0.1×	12	286
Ganesh M. Shankar United States	6	236 1.4×	166 1.2×	115 0.9×	22 0.3×	5 0.1×	8	369
Robert Dingman United States	8	80 0.5×	59 0.4×	80 0.6×	11 0.2×	30 0.5×	13	234
Christelle Capini France	7	267 1.5×	100 0.7×	72 0.6×	103 1.6×	10 0.2×	9	383
Jordi Milá Spain	11	113 0.6×	42 0.3×	56 0.4×	11 0.2×	24 0.4×	17	244
Carl Dolman United Kingdom	7	200 1.1×	113 0.8×	77 0.6×	21 0.3×	5 0.1×	8	305
Gail E. Hawes Netherlands	8	271 1.6×	81 0.6×	21 0.2×	59 0.9×	8 0.1×	13	332
David Eisel Germany	8	264 1.5×	12 0.1×	151 1.2×	20 0.3×	40 0.7×	14	387
Amy E. Gilbert United Kingdom	7	122 0.7×	86 0.6×	76 0.6×	20 0.3×	6 0.1×	11	256
Paulo C. M. Urbano Netherlands	10	133 0.8×	20 0.1×	48 0.4×	47 0.7×	7 0.1×	12	214

Countries citing papers authored by Chi-Kin Chow

Since Specialization

Citations

This map shows the geographic impact of Chi-Kin Chow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chi-Kin Chow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chi-Kin Chow more than expected).

Fields of papers citing papers by Chi-Kin Chow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chi-Kin Chow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chi-Kin Chow. The network helps show where Chi-Kin Chow may publish in the future.

Co-authorship network of co-authors of Chi-Kin Chow

This figure shows the co-authorship network connecting the top 25 collaborators of Chi-Kin Chow. A scholar is included among the top collaborators of Chi-Kin Chow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chi-Kin Chow. Chi-Kin Chow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Benschop, Robert J., Chi-Kin Chow, Yu Tian, et al.. (2019). Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. mAbs. 11(6). 1175–1190. 34 indexed citations

Liu, Ling, Kristine Kikly, Jirong Lu, et al.. (2016). Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. Journal of Inflammation Research. 9. 39–39. 172 indexed citations

Chow, Chi-Kin, Barrett W. Allan, Qing Chai, S. Atwell, & Jirong Lu. (2016). Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure. Molecular Pharmaceutics. 13(3). 915–923. 54 indexed citations

Chintharlapalli, Sudhakar, Johnny E. Croy, Donmienne Leung, et al.. (2016). Abstract 3259: LY3127804, a novel anti-Angiopoietin-2 antibody in combination with an anti-VEGFR2 antibody potently inhibits angiogenesis, tumor growth and metastasis. Cancer Research. 76(14_Supplement). 3259–3259. 1 indexed citations

Zeng, Wei, Victoria L. Peek, Jonathan W. Tetreault, et al.. (2013). Abstract 5465: LY2875358, a bivalent MET antibody with anti-tumor activity through blocking HGF as well as inducing degradation of MET, differentiates from a one-armed 5D5 MET antibody.. Cancer Research. 73(8_Supplement). 5465–5465. 3 indexed citations

Datta‐Mannan, Amita, Chi-Kin Chow, Craig D. Dickinson, et al.. (2012). FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys. Drug Metabolism and Disposition. 40(8). 1545–1555. 47 indexed citations

Zeng, Wei, Lei Yan, Victoria L. Peek, et al.. (2012). Abstract 2734: c-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer. Cancer Research. 72(8_Supplement). 2734–2734. 5 indexed citations

Peek, Victoria L., Wei Zeng, Lei Yan, et al.. (2012). Abstract 2738: c-Met antibody LY2875358 (LA480) has pre-clinical enhanced efficacy with gastric cancer standard-of-care in vitro and in vivo. Cancer Research. 72(8_Supplement). 2738–2738. 4 indexed citations

Zeng, Wei, Wei Yang, Victoria L. Peek, et al.. (2010). Abstract 695: LA480, a c-Met antibody with neutralization and internalization properties, inhibits HGF-dependent and HGF-independent c-Met pathway activation and tumor growth. Cancer Research. 70(8_Supplement). 695–695. 1 indexed citations

10.

Hood, John, Jingyu Cao, Chi-Kin Chow, et al.. (2008). Development of TG101348 for the treatment of JAK2-driven malignancies. Journal of Clinical Oncology. 26(15_suppl). 7083–7083. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact